Sensors for Medicine and Science (SMSI) has secured $54m in Series D equity financing to develop and commercialise an implantable, long-term continuous glucose monitoring system, used to treat diabetes.
The system features a miniaturised sensor, which is inserted into the subcutaneous space, and an external display reader.
Go deeper with GlobalData
The move follows a human pilot study, which demonstrated that the system accurately measured glucose.
The financing round was led by Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.
SMSI plans to use the funds to advance clinical development programmes and regulatory approvals.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
